The comparison of simvastatin and atorvastatín effects on hemostatic parameters in patients with hyperlipidemia type II;Porównanie wpływu simwastatyny i atorwastatyny na wybrane parametry układu krzepniȩcia u chorych z hiperlipidemiaa̧ typu II

Polski Merkuriusz Lekarski

Volumn 18, Issue 106, 2005, Pages 380-384

  Broncel, Marlena ^a   Marczyk, Iwona ^b,d   Chojnowska Jezierska, Julita ^a   Michalska, Marta ^c   Sikora, Joanna ^a   Kostka, Barbara ^c  

^a Zaklad Farmakologii I Terapii Monitorowanej Z Oddzialem Chorob Wewnetrznych

^b Wojewódzki Specjalistyczny Szpital W Łodzi ^*

^c Zak ad Biochemii Farmaceutycznej

^d Wojewodzki Szpital Specjalistyczny   (Poland)

Author keywords

Atorvastatin; Hemostasis; Hyperlipidemia; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBIN III; ATORVASTATIN; BLOOD CLOTTING FACTOR 10; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; FEMALE; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 18444416330     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bickel C., Rupprecht H.J., Blankenberg S. i wsp.: Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int. J. Cardiol., 2002, 82, 25-31.
2. Blann A.D., Gurney D., Hughes E. i wsp.: Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am. J. Cardiol., 2001, 88, 89-92.
3. Camera M., Toschi V., Comparato C. i wsp.: Cholesterol - induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb. Haemost., 2002, 87, 748-55.
4. Chojnowska-Jezierska J.: Pozalipidowe dziatania statyn - nowy kierunek prewencji i terapii antymiażdżycowej. Prob. Ter. Monit., 2000, 11, 61-69.
5. Colucci M., Curatolo L., Donati M.B. i wsp.: Cancer cell procoagulant activity: evaluation by an amidolytic assay. Thromb. Res., 1980, 18, 589-595.
6. Dangas G., Smith D.A., Unger A.H. i wsp.: Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Heamost., 2000, 83, 688-92.
7. Di Garbo V., Bono M., Di Raimondo D. i wsp.: Won lipid, dose dependent effects of pravastatin treatment on hemostatic system and inflammatory response. Eur. J. Clin. Pharmacol., 2000, 56, 277-84.
8. Dick J., McClaren M., Ford R. i wsp.: The effect of atorvastatin on activated factor XII, fibrinogen and lipid profile (abstract). Haemostasis, 2000, 30, 42.
9. Farrer M., Winocour P.H., Evans K. i wsp.: Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res. Clin. Pract., 1994, 23, 111-9.
10. Ferro D., Basili S., Alessandri C. i wsp.: Inhibition of tissue -factor-mediated thrombin generation by simvastatin. Atherosclerosis, 2000, 149, 111-6.
11. Folsom A. R.: Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Tromb. Haemost., 2001, 86, 366-373.
12. Gensini G.F., Comeglio M., Colella A.: Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur. Heart J., 1998, 19 (suppl.A), A53-61.
13. Gentile S., Turco S., Guarino G. i wsp.: Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolemia. Diabetes Obes. Metab., 2000, 2, 355-62.
14. Hamsten A.: The hemostatic system and coronary heart disease. Thromb. Res., 1993, 70, 1-38.
15. Idzior-Waluś B.: Zmiany poziomu wybranych czynników układu hemostatycznego w trakcie leczenia lowastatinem u pacjentów z hiperlipoproteinemia̧ pierwotna̧ II fenotypie II a i II b. Przegla̧d Lek., 1992, 49, 334-340.
16. Jastrzȩbska M.: Fibraty a układ hemostazy. Medipress, 2003, 2, 3-12.
17. Jay R.H., Rampling M.W., Betterige D.J. i wsp.: Abnormalities of blood rheology in familial hypercholesterolemia. Effects of treatment. Atherosclerosis, 1990, 85, 249-51.
18. Joukhadar C., Klein N., Prinz M. i wsp.: Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb. Haemost., 2001, 85, 47-51.
19. Krysiak R., Okopień B., Herman Z.S.: Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs, 2003, 63, 1829-54.
20. Koh K.K., Son J.W., Ahn J.Y. i wsp.: Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease. Am. J. Cardiol., 2003, 91, 1231-33.
21. Marais A.D., Firth J.C., Bateman M.E. i wsp.: Atorvastatin an effective lipid modifying agent in familial hypercholesterolemia. Arterioscl. Thromb. Vasc. Biol., 1996, 17, 1527-31.
22. McEntee M.P., Jesty J., Hultin M.B. i wsp.: Effect or oral contraceptives on antithrombin III. Thromb Res., 1981, 24, 13-20.
23. Michalska M., Kostka B.: Statyny a generacja trombiny w hipercholesterolemii. Probl. Terapii Monit., 2003, 14, 13-18.
24. Mitropoulos K.A., Armitage J.M., Collins R. i wsp.: Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur. Heart. J., 1997, 18, 235-41.
25. Morishita E., Minami S., Ishino C. i wsp.: Atorvastatin reduces plasma levels of factor VII acivity and factor VII antigen in patients with hyperlipidemia. J. Atheroscler. Thromb., 2002, 9, 72-7.
26. Nordoy A., Svenson B., Hansen J.B. i wsp.: Effect of omega-fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler. Thromb. Vasc. Biol., 2000, 154, 203-12.
27. Sbarouni E., Melissari E., Kyriakides Z.S. i wsp.: Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease. Am. J. Cardiol., 2000, 86, 80-3.
28. Szczeklik A., Undas A., Musiał J. i wsp.: Antithrombotic actions of statins. Med. Sci. Monit., 2001, 7, 1381-1385.
29. Szczeklik A., Musiał J., Undas A. i wsp.: Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J. Am. Coll. Cardiol., 1999, 33, 1286-1293.
30. Tan K., Janus E.D., Lam K.S. i wsp.: Effects of fluvastatin on prothrombotic and fibrynolityc factors in type 2 diabetes mellitus. Am. J. Cardiol., 1999, 84, 934-7.
31. Velussi M.: Long term (18 month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk. Nutr. Metal. Cardiovasc. Dis., 2002, 12, 29-35.
32. Wierzbicki A.S., Lumb P.J., Chik G. i wsp.: Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am. J. Cardiol., 2001, 87, 338-340.
33. Wierzbicki A.S., Lumb P.J., Semra Y.K. i wsp.: Effect of atorvastatin on plasma fibrinogen. Lancet, 1998, 351, 569-70.
34. Wilcox J.N., Smith K.M., Schwartz S.M. i wsp.: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci., USA 1989, 86, 2839-43.